Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems - PubMed (original) (raw)
Review
Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems
Ivano Amelio et al. Oncotarget. 2015.
Abstract
Targeting the ubiquitin-proteasome system (UPS) and ubiquitin-like signalling systems (UBL) has been considered a promising therapeutic strategy to treat cancer, neurodegenerative and immunological disorders. There have been multiple efforts recently to identify novel compounds that efficiently modulate the activities of different disease-specific components of the UPS-UBL. However, it is evident that polypharmacology (the ability to affect multiple independent protein targets) is a basic property of small molecules and even highly potent molecules would have a number of "off target" effects. Here we have explored publicly available high-throughput screening data covering a wide spectrum of currently accepted drug targets in order to understand polypharmacology of small molecules targeting different components of the UPS-UBL. We have demonstrated that molecules targeting a given UPS-UBL protein also have high odds to target a given off target spectrum. Moreover, the off target spectrum differs significantly between different components of UPS-UBL. This information can be utilized further in drug discovery efforts, to improve drug efficiency and to reduce the risk of potential side effects of the prospective drugs designed to target specific UPS-UBL components.
Keywords: SUMO; UBC13; UBL; UCH37; UPS.
Conflict of interest statement
Conflicts of Interest
There is no conflict of interest.
Similar articles
- The role of allostery in the ubiquitin-proteasome system.
Liu J, Nussinov R. Liu J, et al. Crit Rev Biochem Mol Biol. 2013 Mar-Apr;48(2):89-97. doi: 10.3109/10409238.2012.742856. Epub 2012 Dec 13. Crit Rev Biochem Mol Biol. 2013. PMID: 23234564 Free PMC article. Review. - Tripartite Split-GFP for High Throughput Screening of Small Molecules: A Powerful Strategy for Targeting Transient/Labile Interactors like E2-E3 Ubiquitination Enzymes.
Polge C, Cabantous S, Taillandier D. Polge C, et al. Chembiochem. 2024 Mar 15;25(6):e202300723. doi: 10.1002/cbic.202300723. Epub 2024 Jan 12. Chembiochem. 2024. PMID: 38088048 Review. - UBL domain of Usp14 and other proteins stimulates proteasome activities and protein degradation in cells.
Kim HT, Goldberg AL. Kim HT, et al. Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11642-E11650. doi: 10.1073/pnas.1808731115. Epub 2018 Nov 28. Proc Natl Acad Sci U S A. 2018. PMID: 30487212 Free PMC article. - A patent review of the ubiquitin ligase system: 2015-2018.
Li X, Elmira E, Rohondia S, Wang J, Liu J, Dou QP. Li X, et al. Expert Opin Ther Pat. 2018 Dec;28(12):919-937. doi: 10.1080/13543776.2018.1549229. Epub 2018 Nov 23. Expert Opin Ther Pat. 2018. PMID: 30449221 Free PMC article. Review. - Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer's disease.
Hong L, Huang HC, Jiang ZF. Hong L, et al. Neurol Res. 2014 Mar;36(3):276-82. doi: 10.1179/1743132813Y.0000000288. Neurol Res. 2014. PMID: 24512022 Review.
Cited by
- Metabolic pathways regulated by TAp73 in response to oxidative stress.
Agostini M, Annicchiarico-Petruzzelli M, Melino G, Rufini A. Agostini M, et al. Oncotarget. 2016 May 24;7(21):29881-900. doi: 10.18632/oncotarget.8935. Oncotarget. 2016. PMID: 27119504 Free PMC article. - Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases.
Kalash L, Val C, Azuaje J, Loza MI, Svensson F, Zoufir A, Mervin L, Ladds G, Brea J, Glen R, Sotelo E, Bender A. Kalash L, et al. J Cheminform. 2017 Dec 30;9(1):67. doi: 10.1186/s13321-017-0249-4. J Cheminform. 2017. PMID: 29290010 Free PMC article. - A Novel Confocal Scanning Protein-Protein Interaction Assay (PPI-CONA) Reveals Exceptional Selectivity and Specificity of CC0651, a Small Molecule Binding Enhancer of the Weak Interaction between the E2 Ubiquitin-Conjugating Enzyme CDC34A and Ubiquitin.
Koszela J, Pham NT, Shave S, St-Cyr D, Ceccarelli DF, Orlicky S, Marinier A, Sicheri F, Tyers M, Auer M. Koszela J, et al. Bioconjug Chem. 2024 Sep 18;35(9):1441-1449. doi: 10.1021/acs.bioconjchem.4c00345. Epub 2024 Aug 21. Bioconjug Chem. 2024. PMID: 39167708 Free PMC article. - P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development.
Velletri T, Xie N, Wang Y, Huang Y, Yang Q, Chen X, Chen Q, Shou P, Gan Y, Cao G, Melino G, Shi Y. Velletri T, et al. Cell Death Dis. 2016 Jan 21;7(1):e2015. doi: 10.1038/cddis.2015.367. Cell Death Dis. 2016. PMID: 26775693 Free PMC article. Review. - SUMO, a small, but powerful, regulator of double-strand break repair.
Garvin AJ, Morris JR. Garvin AJ, et al. Philos Trans R Soc Lond B Biol Sci. 2017 Oct 5;372(1731):20160281. doi: 10.1098/rstb.2016.0281. Philos Trans R Soc Lond B Biol Sci. 2017. PMID: 28847818 Free PMC article. Review.
References
- Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nature reviews Molecular cell biology. 2005;6:599–609. - PubMed
- Blagosklonny MV, Wu GS, Omura S, ElDeiry WS. Proteasome-dependent regulation of p21(WAF1/CIP1) expression. Biochemical and biophysical research communications. 1996;227:564–569. - PubMed
- Blagosklonny MV. Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors. Oncogene. 2001;20:395–398. - PubMed
- Hershko A, Heller H, Elias S, Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. The Journal of biological chemistry. 1983;258:8206–8214. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous